SG181127A1 - Therapies for preventing or suppressing clostridium difficile infection - Google Patents

Therapies for preventing or suppressing clostridium difficile infection Download PDF

Info

Publication number
SG181127A1
SG181127A1 SG2012039616A SG2012039616A SG181127A1 SG 181127 A1 SG181127 A1 SG 181127A1 SG 2012039616 A SG2012039616 A SG 2012039616A SG 2012039616 A SG2012039616 A SG 2012039616A SG 181127 A1 SG181127 A1 SG 181127A1
Authority
SG
Singapore
Prior art keywords
toxin
antibody
difficile
antibodies
trypsin
Prior art date
Application number
SG2012039616A
Other languages
English (en)
Inventor
Clifford Shone
April Roberts
John Landon
Original Assignee
Health Prot Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2010/050288 external-priority patent/WO2010094970A1/en
Application filed by Health Prot Agency, Micropharm Ltd filed Critical Health Prot Agency
Publication of SG181127A1 publication Critical patent/SG181127A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG2012039616A 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection SG181127A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0921288.7A GB0921288D0 (en) 2009-12-04 2009-12-04 Therapies for preventing or suppressing clostridium difficile infection
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins
PCT/GB2010/052035 WO2011067616A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection

Publications (1)

Publication Number Publication Date
SG181127A1 true SG181127A1 (en) 2012-07-30

Family

ID=41641956

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2012039616A SG181127A1 (en) 2009-12-04 2010-12-06 Therapies for preventing or suppressing clostridium difficile infection

Country Status (10)

Country Link
US (1) US8921529B2 (enExample)
EP (1) EP2506877B1 (enExample)
JP (1) JP5877161B2 (enExample)
CN (1) CN102740889A (enExample)
BR (1) BR112012013496A2 (enExample)
CA (1) CA2782639C (enExample)
GB (1) GB0921288D0 (enExample)
MY (1) MY158712A (enExample)
SG (1) SG181127A1 (enExample)
WO (1) WO2011067616A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
KR101907434B1 (ko) 2010-09-03 2018-10-12 발네바 오스트리아 게엠베하 C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
AR086199A1 (es) 2011-04-22 2013-11-27 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos
US9505847B2 (en) 2011-08-22 2016-11-29 Cnj Holdings Inc Clostridium difficile antibodies
AU2012349753A1 (en) 2011-12-08 2014-06-19 Novartis Ag Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US20160002278A1 (en) 2013-03-08 2016-01-07 Cipla Limited Pharmaceutical Compositions for Rectal Administration
HK1213917A1 (zh) * 2013-03-15 2016-07-15 Sanofi Pasteur, Inc. 類霉素、組合物及相關方法
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US10513552B2 (en) 2014-06-20 2019-12-24 Immunimed Inc. Use of polyclonal antibodies against clostridium difficile for treatment of inflammatory bowel disease
EP2957570B1 (en) * 2014-06-20 2019-04-17 Immunimed Inc. Polyclonal antibodies against clostridium difficile and uses thereof
CN106659799B (zh) * 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗
EP3121272A1 (en) * 2015-07-24 2017-01-25 Zymetech ehf. Novel fish trypsin isoforms and their use
US20190111001A1 (en) * 2016-03-30 2019-04-18 University Of Maryland, Baltimore Microparticulate system for colonic drug delivery
GB201701404D0 (en) 2017-01-27 2017-03-15 Micropharm Ltd Therapies for treating inflammatory disorders
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN115704021A (zh) * 2021-08-17 2023-02-17 上海宝济药业有限公司 一种人糜蛋白酶原及其制备方法和应用
WO2026036320A1 (zh) * 2024-08-15 2026-02-19 中国科学院上海有机化学研究所 一种靶向酶蛋白药物及其设计方法
WO2026085370A2 (en) * 2024-10-16 2026-04-23 Triveni Bio, Inc. Dual inhibitor trypsin antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) * 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
WO1996007430A1 (en) 1994-09-06 1996-03-14 Galagen, Inc. Therapeutic treatment of clostridium difficile associated diseases
JP2002514886A (ja) * 1994-10-24 2002-05-21 プロメガ コーポレーション クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
EP2305303A3 (en) 1997-10-20 2013-11-13 Sanofi Pasteur Biologics Co. Immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US20020009429A1 (en) 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
ES2366626T3 (es) * 2004-02-06 2011-10-24 University Of Massachusetts Anticuerpos contra toxinas de clostridium difficile y usos de los mismos.
EP1750743A4 (en) * 2004-04-29 2009-07-08 Glaxosmithkline Zagreb ORAL PREPARATIONS CONTAINING BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF METABOLIC BONE DISEASES
CA2592015A1 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
CN101363867B (zh) 2008-05-26 2012-12-19 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条及其制备方法
US8709428B2 (en) 2009-02-20 2014-04-29 Health Protection Agency Antibodies to Clostridium difficile toxins
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
JP2013512889A (ja) 2013-04-18
GB0921288D0 (en) 2010-01-20
US20130004561A1 (en) 2013-01-03
AU2010325764A1 (en) 2012-06-07
MY158712A (en) 2016-11-15
EP2506877B1 (en) 2021-08-04
BR112012013496A2 (pt) 2016-08-16
WO2011067616A1 (en) 2011-06-09
JP5877161B2 (ja) 2016-03-02
EP2506877A1 (en) 2012-10-10
US8921529B2 (en) 2014-12-30
CA2782639C (en) 2019-02-26
CN102740889A (zh) 2012-10-17
CA2782639A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
CA2782639C (en) Therapies for preventing or suppressing clostridium difficile infection
AU2010215275B2 (en) Antibodies to Clostridium difficile toxins
JP3914484B2 (ja) 可溶性組換えボツリヌス毒素タンパク
CN113490686A (zh) 病原体结合蛋白
US20100150942A1 (en) Affinity purified human polyclonal antibodies and methods of making and using them
CN113289012B (zh) 治疗和/或预防艰难梭菌相关疾病的方法和组合物
JPH11506424A (ja) ベロ毒素産生大腸菌に対する治療
Zhang et al. Potential therapeutic effects of egg yolk antibody (Igy) in helicobacter pylori infections─ A review
US20210347876A1 (en) Therapies for treating inflammatory disorders
Sanchez et al. Inhibition of adhesion of enterotoxigenic Escherichia coli cells expressing F17 fimbriae to small intestinal mucus and brush-border membranes of young calves
AU2010325764B2 (en) Therapies for preventing or suppressing Clostridium difficile infection
HK1173646A (en) Therapies for preventing or suppressing clostridium difficile infection
HK1173646B (en) Therapies for preventing or suppressing clostridium difficile infection
Ellis et al. Evaluation of a toxoid for protection of rabbits against enteroxaemia experimentally induced by trypsin-activated supernatant of Clostridium spiroforme
RO138173A2 (ro) Utilizarea imunoglobulinelor y în tratamentul fibrozei chistice-infecţia cu pseudomonas aeruginosa, a infecţiei cu mycobacterium tuberculosis şi infecţiei cu helicobacter pylori
KR100497700B1 (ko) 용해성재조합보툴리누스독소단백질
AU2521600A (en) Treatment for verotoxin-producing escherichia coli